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Introduction: Hemangioblastomas are highly vascular tumors that can arise within the central nervous system as
well as other organ systems within the body. They can arise sporadically or as part of von Hippel–Lindau syndrome.
Those arising in critical locations within the central nervous system can be difficult to resect surgically and therefore
pose a significant challenge and result in morbidity and even mortality. Hemangioblastomas express high levels of
vascular endothelial growth factor that drives angiogenesis and tumor progression. We hypothesized that
bevacizumab through its inhibitory effect on vascular endothelial growth factor will result in hemangioblastoma
tumor regression as well as a meaningful clinical response.
Case presentation: We present the case of a 51-year-old Caucasian man with surgically unresectable cervical cord
hemangioblastoma presenting with progressive weakness leading to quadriparesis. He was treated with
bevacizumab and his follow up magnetic resonance imaging scans showed marked tumor regression. After only six
cycles of intravenous bevacizumab (10mg/kg every two weeks), he started ambulating after being wheelchair
bound. He is currently still receiving treatment almost two years after initiation of bevacizumab.
Conclusions: We have shown for the first time that bevacizumab can result in significant tumor regression and a
sustained clinical improvement in a patient with an otherwise unresectable spinal cord hemangioblastoma. This
novel approach can be immensely useful for patients with difficult to resect hemangioblastomas or those with
multiple lesions such as in von Hippel–Lindau syndrome.Introduction
Central nervous system (CNS) hemangioblastomas are
highly vascular tumors that commonly arise in the brain
and less commonly in the spinal cord [1]. Despite their
histologically benign nature, they often result in signifi-
cant neurological disability based upon their location.
These tumors express high levels of vascular endothelial
growth factor (VEGF) which drives angiogenesis, a
process that explains their highly vascular nature [2].
Tumors located within accessible locations in the CNS
are commonly treated with surgical resection followed by
radiation treatment for incompletely resected or recur-
rent lesions [3]. A complete resection of these tumors
typically results in a cure. However, tumors located in
critical locations are occasionally unresectable and,Correspondence: aomar@siumed.edu
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reproduction in any medium, provided the ortherefore, cures are rarely achieved with non-operative
management such as radiation therapy [4]. Furthermore,
radiation carries the risk of increasing peritumoral edema
as well as the potential for development of radiation ne-
crosis [5]. To date, chemotherapy and/or targeted agents
play a limited role in this patient population [6].
Given their high levels of VEGF expression, blocking
the VEGF pathway would be an appealing target for con-
trolling angiogenesis and subsequently tumor growth.
Bevacizumab is a humanized monoclonal antibody that
binds to the VEGF protein and inhibits its interaction
with the VEGF receptor [7]. It is, therefore, a logical can-
didate for the treatment of surgically unresectable
hemangioblastomas. This targeted agent was recently
approved by the US Food and Drug Administration
(FDA) for the treatment of recurrent glioblastoma, but to
the best of our knowledge, there are no published reports
of spinal cord hemangioblastoma regression followingis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as thalidomide have been tested in the past with
stabilization of spinal cord hemangioblastoma in a
pediatric patient with von Hippel–Lindau syndrome
(VHL) [8]. In addition, a more recent report indicates
that retinal hemangioblastomas may respond favorably
to bevacizumab [9]. Another case report showed that
treatment with intravitreal bevacizumab had no effect on
a hemangioblastoma of the optic nerve head [10]. To the
best of our knowledge, our report is the first to show
tumor regression as well as sustained and meaningful
clinical improvement in a patient with unresectable
spinal cord hemangioblastoma treated with bevacizumab.Case presentation
A 51-year-old Caucasian man with a four-year history of
left hand pain, dysesthesia and weakness that progressed
over the subsequent year to involve the left upper ex-
tremity presented to our clinic. He was initially diag-
nosed with Raynaud’s disease and treated with
nifedipine. His pain continued to worsen and later pro-
gressed to involve bilateral upper extremities all the way
up to the elbows. Over the subsequent two to three
years he developed progressive right upper extremity as
well as bilateral lower extremity weakness. Neurologic
examination revealed quadriparesis and impaired sensa-
tion to all modalities over bilateral upper extremities upFigure 1 Bevacizumab resulted in tumor regression of a cervical cord
imaging view of the cervical spine, post gadolinium-diethylene triamine pe
demonstrate the pre-bevacizumab baseline scan. Figure 1B (sagittal) and 1
bevacizumab. Figure 1C (sagittal) and 1F (axial) demonstrate further reduct
bevacizumab.to the elbows and bilateral lower extremities up to a few
inches below the waistline.
He underwent a magnetic resonance imaging (MRI) of
the brain and cervical spine which showed a 2.7 × 1.1 ×
1.5cm avidly enhancing intramedullary lesion at C2-C4
with a cervical cord syrinx, marked cord edema and ex-
pansion, extending from the medulla through T3. He
was taken to the operating room and an attempt at sur-
gical resection was unsuccessful due to the lack of a
defined surgical plane and the high vascularity of the
tumor mass. A biopsy was performed which confirmed
the diagnosis of hemangioblastoma. The syrinx was not
entered or drained during this procedure. The patient
refused testing for von Hippel–Lindau disease but no
other hemangioblastomas were seen on whole neuraxis
scanning and fundoscopic examination. Postoperatively
he continued to deteriorate to the extent that he became
wheelchair bound. Oral dexamethasone (16mg daily)
was initiated approximately one week postoperatively
because of increasing arm weakness and he showed min-
imal improvement. The improvement was short-lived
and dexamethasone was subsequently tapered over the
ensuing two to three weeks.
Bevacizumab was started after obtaining appropriate
informed consent. The patient was given a 10mg/kg in-
fusion every two weeks (initially for two cycles) and an
MRI of the cervical spine was obtained. The MRI
revealed significant improvement in the T2 signalhemangioblastoma. This is a sagittal and axial magnetic resonance
ntaacetic acid administration. Figure 1A (sagittal) and 1D (axial)
E (axial) demonstrate tumor regression following two cycles of
ion in the enhancing tumor following an additional four cycles of
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crease in the size of enhancing disease from 2.7 × 1.0 ×
1.5cm to 2.2 × 1.0 × 1.5cm (Figure 1A, 1B, 1D and 1E).
His arm strength improved from 3/5 to 4/5 bilaterally
but he was receiving rehabilitation treatment during that
time. He remained wheelchair bound with 2/5 strength
in both lower extremities. Four additional cycles of beva-
cizumab were given (to a total of six cycles) and a repeat
MRI showed a further decrease in tumor dimensions,
now measuring 2.0 × 0.8 × 1.5cm (Figure 1C and 1F).
He subsequently developed arthralgia and elected to
stop bevacizumab treatment but he had already started
taking a few steps with assistance. Bevacizumab was
restarted after several months and he showed slow clin-
ical improvement. Currently, he is able to ambulate
about 200 feet with minimal assistance after two years of
bevacizumab treatment.Discussion
Hemangioblastomas are benign highly vascular central
nervous system tumors. They represent 1.5% to 2.5% of
all intracranial tumors, the majority of which are located
within the cerebellar hemispheres [1]. Other CNS loca-
tions are less common and include the cerebral hemi-
spheres (9%), brainstem (5%), and spinal cord (7%) [1].
They may occur as part of the VHL complex in up to
25% of cases or more commonly as sporadic lesions in
up to approximately 75% of cases [11].
The molecular pathogenesis of hemangioblastomas is
not fully understood; however, in VHL disease the genetic
mutation had been previously elucidated. The disease is
linked to a mutation of the VHL gene on chromosome
3p25-26 which transcribes VHL protein (pVHL) [12].
This protein is normally responsible for degradation of
the hypoxia-inducible factor (HIF) transcriptional com-
plex. Under hypoxic conditions, HIF upregulates expres-
sion of growth factors, such as vascular endothelial
growth factor (VEGF), platelet-derived growth factor
(PDGF), and erythropoietin. Loss of VHL function results
in deregulated HIF activity and overexpression of VEGF
leading to hemangioblastomas [11]. Since VEGF and its
receptors appear to play a crucial role in hemangioblas-
toma tumorigenesis, we hypothesized that blocking the
VEGF pathway might result in disruption of tumor angio-
genesis and consequently tumor regression. In this report,
we demonstrate for the first time the successful treatment
of a surgically unresectable cervical cord hemangioblas-
toma using bevacizumab (a monoclonal antibody directed
against VEGF) [7]. Bevacizumab is currently used for the
treatment of a variety of solid tumors including recurrent
glioblastomas, metastatic colorectal carcinoma, and
breast cancer as well as renal cell carcinoma [7]. Intravi-
treal bevacizumab was attempted in previous series forthe treatment of retinal hemangioblastomas with varying
degrees of success [9,10].
Current treatment options for patients with CNS
hemangioblastomas include surgical resection as well as
adjuvant stereotactic radiosurgery for incompletely
resected or recurrent lesions [13,14]. Although gross
total resection commonly results in excellent outcomes,
in some circumstances given the highly vascular nature
of these tumors, a gross total resection is not feasible.
For example, in one series a gross total resection was
achieved in only three of six patients (50%) with intra-
medullary spinal cord hemangioblastomas [4]. In these
instances, radiosurgery is commonly employed for in-
completely resected lesions. However, the therapeutic ef-
ficacy of radiosurgery diminishes over time and post-
radiation swelling can result in significant morbidity and
neurologic decline [14]. In addition, radiation necrosis
has been reported following radiosurgical treatment, a
complication which can result in poor outcomes for
those patients [5].
Development of a systemic approach would, therefore,
offer an attractive alternative for patients with surgically
unresectable hemangioblastomas, those with medical
comorbidities that may preclude surgery as well as
patients with multiple hemangioblastomas as can be
seen with the VHL complex. We have shown that the
systemic infusion of bevacizumab can result in heman-
gioblastoma tumor regression as well as a sustained and
meaningful clinical improvement. This effect may poten-
tially be attributed to a decrease in vascular permeability
and subsequent improvement of edema, regression of
angiogenesis or a combination of both. Further studies
are needed to define better the role of bevacizumab in
the treatment of this challenging disease.Conclusions
Only one case report was found in a Medline search
(keywords: bevacizumab; hemangioblastoma) that showed
retinal hemangioblastomas may respond favorably to
intravitreal bevacizumab [9]. To the best of our
knowledge, this is the first report to demonstrate that
bevacizumab results in a positive radiographic response
as well as significant clinical improvement (from
wheelchair-bound to ambulating with minimal assist-
ance) when used to treat a surgically unresectable spinal
cord hemangioblastoma.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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